TUSTIN, Calif., May 14 /PRNewswire-FirstCall/ -- AMDL, Inc. , headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products.
AMDL announced today that Jade, through its subsidiary JJB, has signed a new Distribution and Agency Agreement with Shanghai SiFul Medicine Co., Ltd., (Shanghai SiFul), an indirect subsidiary of China Resources (Holdings) Co., Ltd. (China Resources). This one-year renewable agreement covers primarily the city of Shanghai. Shanghai SiFul will initially be selling 12 various Jade products including Ondansetron Injectables, Domperidon Tablets, Chondroitin Sulfate Injectables, GuYanLin Compounds, Benzoic Acid /Camphor Solutions, Levofloxacin and Lactate Injectables and others.
Mr. Frank Zheng, Managing Director of JPI, stated that “the total population of Shanghai is over 20 million people, with one of the most affluence population bases within China today. Gaining market share for JPI’s products in this key China market is a cornerstone of our sales growth strategy. This new distribution agreement with Shanghai SiFul, coupled with the new distribution relationship recently announced with Double Crane Medicine Co. Ltd. (Changsha), both require JJB’s distribution partners to meet minimum sales thresholds of approximately (US) $3.8 million annually or a total of (US) $7.6 million for these two contracts. Based upon both distribution agreements and discussions between JJB and its new distribution partners, there is a potential to increase JPI’s sales in Southern China and the Shanghai regional markets by as much as (US) $16 million over the next 12 month sales cycle. Ondansetron injectables are expected to be the biggest selling product in the Shanghai hospital marketplace.”
Mr. Gary Dreher, CEO of AMDL noted that that this “new regional Chinese distribution relationship with Shanghai SiFul is truly exciting and significantly enhances JPI’s ability to grow its sales in this key China market.”
About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
About Shanghai SiFul: Shanghai SiFul is an indirect subsidiary of China Resources. Shanghai SiFul’s 2006 sales were approximately (US) $80 million. Shanghai SiFul’s sales activities are nearly all focused on the Shanghai market. China Resources began its history in Hong Kong in 1938 as Liow & Company. It was renamed China Resources Company in 1948 and restructured and incorporated under China Resources (Holdings) Co., Ltd. in 1983. In the same year, it relocated to its current headquarters in the China Resources Building on 26 Harbour Road, Wanchai. With more than a half century’s business in Hong Kong, China Resources has established a strong reputation based on its proactive business strategies, an open corporate culture and a commitment to fostering a better future. Today, it is one of the leading conglomerates in Hong Kong and the Chinese Mainland, with assets totaling approximately (US) $14 Billion.
About AMDL: AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at www.amdl.com.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460
AMDL, Inc.
CONTACT: AMDL, Inc., Gary L. Dreher, President & CEO, +1-714-505-4460
Web site: http://www.amdl.com/
